LAB: Fluidigm Market Cap to Earnings

Fluidigm - graphic logo of issuer LAB

Can Standard BioTools Inc. (LAB) exercise pricing power amid a reduction in global R&D spending? A steady cash cow is provided by the sale of consumables and chips for molecular analysis. The P/E volatility of the company on GURU.Markets reflects the real-time valuation of the business, where the value -3.90 captures the metric level, confirming its leadership in creating microfluidic tools for the precise study of biomolecules.

Standard BioTools (LAB) P/E Multiple: for the period 04/28/2023 - 11/10/2026

Analytical breakdowns for Standard BioTools Inc.

- stock quotes and analyst forecast:
Price Chart fluidigm.com|LAB - Consensus Target
- market capitalization information:
Market Value Standard BioTools Inc.|LAB - Total Company Value
- book value of equity indicators:
Net Assets per Share Standard BioTools|LAB - Book Capitalization|Market Capitalization to Book Value fluidigm.com|LAB - Aggregate Company Assets
- company liabilities and liquidity data:
Total Debt to Capital Coefficient Standard BioTools Inc.|LAB - Long-Term Debt to Equity|Short-Term Debt to Capital Coefficient Standard BioTools Corp|LAB - Company Total Debt|Debt to Book Capital Standard BioTools Inc.|LAB - Company Long-Term Debts|Company Short-Term Debts Standard BioTools|Immediate Liquidity Ratio fluidigm.com
- earnings and market multiples details:
LAB - Net Profit|Net Profit Forecast Standard BioTools Inc.|LAB - P/E Multiple|Forward P/E Multiple Standard BioTools Inc|LAB - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation Standard BioTools Inc.|LAB - Operating profit EBITDA|Earnings per share for the last 12 months Standard BioTools|LAB - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months fluidigm.com|LAB - Earnings growth in current year|Net earnings per share growth forecast for next year Standard BioTools Inc.
General company analysis:fluidigm.com, LAB
Manufactured product of Standard BioTools Inc.

P/E measures the investment payback period via the ratio of a stock's market value to net income, determining the extent of the asset's overvaluation. For Standard BioTools Inc. (LAB), with its production and logistics outsourcing model, this P/E chart reflects the efficiency of delegating operating expenses, allowing investors to assess the fundamental value of the business relative to its actual profitability.

Key competitors

Price to Earnings Ratio A|Price to Earnings Ratio DGX (Quest Diagnostics Incorporated)|ILMN - Market Cap to Earnings|Price to Earnings Ratio Cologuard EXAS|Business Payback Period Revvity Corp (RVTY)|Bio-Rad Laboratories - P/E Multiple|Business Payback Period anbio.com NNNN|Sotera Health (SHC) - Price to Earnings Ratio|QDEL - Business Payback Period|Price to Earnings Ratio OPKO Corp|caredx.com (CDNA) - Business Payback Period|Price to Earnings Ratio MRVI (Maravai LifeSciences)|Market Price to Net Income Ratio FLGT|P/E Multiple CTKB (Cytek Biosciences)|P/E Multiple OraSure Technologies, Inc. OSUR|XGN - Price to Earnings Ratio|MDXH (MDxHealth, Inc.) - Price to Earnings Multiple|LUCD: P/E Multiple|Price to Earnings Multiple PRE|IMDX (Insight Molecular Diagnostics, Inc.) - P/E Multiple|P/E Multiple Trinity Biotech Corp|Price to Earnings Ratio ProPhase (PRPH)|AIMD (Ainos Corporation) - Company Value to Net Income|P/E Multiple CODX (Co-Diagnostics, Inc.)|HSCS: Price to Earnings Multiple|BMRA: Price to Earnings Ratio|Company Value to Net Income CDIO (Cardio Diagnostics)|ONCO: P/E Multiple|VRAX (Virax Biolabs Corp) - Price to Earnings Ratio|BJDX (Bluejay Diagnostics) - P/E Multiple|aspirawh.com (AWH) - Business Payback Period|Price to Earnings Ratio Accelerate Diagnostics, Inc. (AXDX)|CNTG - Market Cap to Earnings|Enzo Biochem - Price to Earnings Ratio|Market Price to Net Income Ratio FRES (Fresh2 Group Ltd)|GENE - Price to Earnings Ratio|Market Cap to Earnings 23andme.com|Psychemedics Corporation (PMD) - Price to Earnings Ratio